These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19598262)

  • 1. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
    Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
    Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.
    Kim A; Serada S; Enomoto T; Naka T
    Expert Opin Ther Targets; 2010 Sep; 14(9):963-71. PubMed ID: 20673185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers.
    Matsuzaki S; Serada S; Morimoto A; Ueda Y; Yoshino K; Kimura T; Naka T
    Expert Opin Ther Targets; 2014 Apr; 18(4):403-14. PubMed ID: 24479491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.
    Matsuzaki S; Enomoto T; Serada S; Yoshino K; Nagamori S; Morimoto A; Yokoyama T; Kim A; Kimura T; Ueda Y; Fujita M; Fujimoto M; Kanai Y; Kimura T; Naka T
    Int J Cancer; 2014 Apr; 134(8):1796-809. PubMed ID: 24150977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.
    Takaya A; Peng WX; Ishino K; Kudo M; Yamamoto T; Wada R; Takeshita T; Naito Z
    Int J Oncol; 2015 Apr; 46(4):1573-81. PubMed ID: 25633807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary.
    Choi CH; Sung CO; Kim HJ; Lee YY; Song SY; Song T; Kim J; Kim TJ; Lee JW; Bae DS; Kim BG
    Hum Pathol; 2013 Jun; 44(6):1017-23. PubMed ID: 23290009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells.
    Mogami T; Yokota N; Asai-Sato M; Yamada R; Koizume S; Sakuma Y; Yoshihara M; Nakamura Y; Takano Y; Hirahara F; Miyagi Y; Miyagi E
    PLoS One; 2013; 8(11):e80359. PubMed ID: 24244679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
    Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
    Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo.
    Li M; Yin J; Mao N; Pan L
    Oncol Rep; 2013 Jan; 29(1):58-66. PubMed ID: 23064469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
    Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
    Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
    Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
    Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annexin IV is differentially expressed in clear cell carcinoma of the ovary.
    Miao Y; Cai B; Liu L; Yang Y; Wan X
    Int J Gynecol Cancer; 2009 Dec; 19(9):1545-9. PubMed ID: 19955935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
    Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
    J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
    Itamochi H; Kigawa J; Terakawa N
    Cancer Sci; 2008 Apr; 99(4):653-8. PubMed ID: 18377417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.
    Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
    J Gynecol Oncol; 2017 May; 28(3):e33. PubMed ID: 28382796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma.
    Ohishi Y; Oda Y; Uchiumi T; Kobayashi H; Hirakawa T; Miyamoto S; Kinukawa N; Nakano H; Kuwano M; Tsuneyoshi M
    Clin Cancer Res; 2002 Dec; 8(12):3767-75. PubMed ID: 12473588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
    Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
    Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.